J. Mezger

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Martin Reck, Joachim von Pawel, Petr Zatloukal et al. · Journal of Clinical Oncology · 2009 · 1.5K citations

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Martin Reck, Joachim von Pawel, Petr Zatloukal et al. · Annals of Oncology · 2010 · 640 citations · Full text

First-line Therapy, Oncology, Overall Survival +8

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

Richard J. Gralla, M. Lichinitser, S. van der Vegt et al. · Annals of Oncology · 2003 · 471 citations

Emetogenic Chemotherapy, Oncology, Chemotherapy-induced Nausea +5

Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin’s Lymphoma: Results of the HD8 Trial of the German Hodgkin’s Lymphoma Study Group

Andreas Engert, Petra Schiller, Andreas Josting et al. · Journal of Clinical Oncology · 2003 · 456 citations

Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

Joachim von Pawel, Robert M. Jotte, David R. Spigel et al. · Journal of Clinical Oncology · 2014 · 333 citations · Full text